-- 根據路透社週四援引消息人士報道，私募股權巨頭阿波羅全球管理公司 (Apollo Global Management, APO)、黑石集團 (Blackstone, BX) 和 KKR 集團 (KKR) 已進入殼牌公司 (Shell, SHEL) 持有的加拿大液化天然氣項目 (LNG Canada) 40% 股份的最終競標。 由於北美能源能夠為目前受伊朗戰爭影響而中斷的供應提供穩定的替代方案，該項目的吸引力日益增強。 加拿大液化天然氣計畫地理位置優越，可直達太平洋，是北美第一個能夠將液化天然氣直接輸送至亞洲主要市場的大型設施。 報導稱，該交易價值可能在 100 億至 150 億美元之間，殼牌公司將能夠出售其部分股份，並為這家位於不列顛哥倫比亞省的設施的未來擴建吸引新的資金。 報告指出，殼牌公司計劃將其在該專案一期和第二期工程中的股份全部出售給單一競標者，而不是分拆出售。 包括競標公司在內的所有相關方均未立即回覆的置評請求。 （市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源，但可能包含傳聞和猜測。準確性無法保證。）
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
$FE
Sectors
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
$LW
Australia
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%
$AZN